sirolimus / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

159 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sirolimus / Generic mfg.
ACTRN12622000480785p: The Effect of Regular Exercise & Intermittent Rapamycin Dosing On Muscle Performance In Older Adults

Not yet recruiting
2
40
 
Vitality Healthspan Foundation, VitaDao
sarcopenia
 
 
2021-006702-78: Open-label study to assess safety and efficacy of rapamycin in drug-resistant epilepsy associated with mTOR pathway pathologies Ocena bezpieczeństwa i skuteczności rapamycyny w leczeniu rzadkich padaczek wieku dziecięcego

Not yet recruiting
2
50
Europe
Rapamune 1mg/ml oral solution, Oral solution, Rapamune 1 mg/ml oral solution
The Children's Memorial Health Institute, Medical Research Agency
epilepsy, mTORopathies, focal cortical dysplasia, LEATS padaczka, „mTORopatie”, ogniskowa dysplazja korowa, LEATS, epilepsy, mTORopathies, focal cortical dysplasia, LEATS padaczka, „mTORopatie”, ogniskowa dysplazja korowa, LEATS, Diseases [C] - Nervous System Diseases [C10]
 
 
ACTRN12622000480785: Rapamycin impact on muscle strength and endurance in older adults

Withdrawn
2
40
 
Dr Brad Stanfield Ltd, Vitasang Ltd, none
sarcopenia
 
 
ACTRN12619000268145: A multi-centre trial of a new immunosuppression regime for pancreatic islet transplant recipients

Recruiting
2
15
 
The University of Sydney, JDRF Australia
Hypoglycaemia Unawareness, Type 1 Diabetes, Islet graft survival
 
 
ACTRN12624000790549: Rapamycin impact on muscle strength and endurance in older adults

Recruiting
2
40
 
Dr Brad Stanfield Ltd, Dr Brad Stanfield Ltd
Sarcopenia
 
 
NCT00544115: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting
2
260
NA
busulfan, cyclophosphamide, cyclosporine, etoposide, fludarabine phosphate, melphalan, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
03/07
12/24
2008-002310-22: A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients

Ongoing
2
20
Europe
Coated tablet, RAPAMUNE*100CPR RIV 2MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Graft Versus Host Disease
 
 
2011-001534-42: Clinical study in which are enrolled patients with malignant hematologic diseases for which there is no indication for allogeneic bone marrow transplantation, and for whom a suitable donor has been identified (fully compatible or partially compatible). Studio clinico nel quale vengono arruolati pazienti affetti da malattie ematologiche maligne, per i quali ci sia indicazione a trapianto di midollo osseo allogenico, e per i quali sia stato individuato un donatore idoneo (totalmente compatibile o parzialmente compatibile).

Ongoing
2
154
Europe
Powder for solution for infusion, Solution for infusion, Tablet, Coated tablet, FLUDARA*EV 5FL 50MG, OVASTAT, ATG FRESENIUS S, MABTHERA*EV 1FL 50ML 500MG, RAPAMUNE*30CPR RIV 2MG, MYFORTIC*250CPR RIV 360MG
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, MEDAC, FRESENIUS BIOTECH
Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched family is from the register. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da patologie maligne ematologiche (leucemia, mieloma, linfoma), candidati a trapianto allogenico da donatore HLA-identico o HLA- mismatched sia familiare che da registro., Pediatric and adult patients (aged 1 to 70 years) suffering from blood cancer (leukemia, lymphoma, etc..) to be undergoing bone marrow transplantation. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da tumori del sangue (leucemie, linfomi etc.) che dovranno essere sottoposti a trapianto di midollo osseo., Diseases [C] - Immune System Diseases [C20]
 
 
2012-001106-26: TRIAL PHASE II MULTICENTER FOR CANCER PATIENTS DIAGNOSED WITH OSTEOSARCOMA WITH METASTASIS WHO HAVE ALREADY BEEN TREATED PREVIOUSLY ESTUDIO FASE II MULTICENTRICO PARA PACIENTES DIAGNOSTICADOS DE CANCER TIPO OSTEOSARCOMA CON METASTASIS QUE YA HAN SIDO TRATADOS PREVIAMENTE

Ongoing
2
33
Europe
Concentrate and solvent for solution for infusion, Oral solution, GEMCITABINE, RAPAMUNE
JAVIER MARTÍN BROTO, Dirección General de Farmacia y Productos Sanitarios del Ministerio de Sanidad, Política Social e Igualdad
Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination. Pacientes diagnosticados de osteosarcoma metastásico que han sido tratados con quimioterapia y tienen enfermedad que permite recibir esta combinación de tratamiento., Patients with metastatic osteosarcoma cancer that have been treated with standard chemotherapy and have active disease requiring treatment. Pacientes diagnosticados de cáncer tipo osteosarcoma metastásico que han sido tratados y tienen enfermedad activa, necesitando recibir tratamiento para su enfermedad., Diseases [C] - Cancer [C04]
 
 
2012-000301-71: Preventing the bone marrow graft from attacking the host's organs by injection of regulatory cells.

Ongoing
2
35
Europe
regulatory T cells, Treg, Infusion, Tablet, Rapamune
CHU-ULg
Steroid-refractory chronic graft-versus-host-disease., A complication of bone marrow transplants in which donor T cells contained in the graft attack the host's tissues.Treatment with corticosteroids has failed to control this attack., Body processes [G] - Biological Phenomena [G16]
 
 
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting
2
19
US
sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
06/13
10/13
ACTRN12613001321730: Sirolimus plus prednisone for the treatment of Erdheim-Chester Disease: a pilot study

Active, not recruiting
2
10
 
University of Parma, Department of Clinical and Experiment Medicine, Department of Clinical and Experimental Medicine, University of Parma
Erdheim-Chester disease
 
 
NCT00652990: Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I

Active, not recruiting
2
18
US
Sirolimus
University of Alabama at Birmingham, National Cancer Institute (NCI)
Neurofibromatosis Type 1, Plexiform Neurofibromas, Paraspinal Plexiform Neurofibromas
08/14
08/14
2007-007907-34: Conversione della terapia immunosoppressiva a Sirolimus (Rapamune) monoterapia per complicanze da inibitori della calcineurina, in pazienti sottoposti a trapianto ortotopico di fegato.

Ongoing
2
50
Europe
RAPAMUNE, RAPAMUNE
AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Pazienti ospedalizzati sottoposti a trapianto di fegato da cadavere o da donatore vivente entro 12 mesi dall\'arruolamento
 
 
2007-005477-54: Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies Condizionamento a base di Treosulfano e profilassi della GvHD con Rapamicina, nel trapianto allogenico non manipolato da donatori alternativi per la cura di patologie neoplastiche ematologiche.

Ongoing
2
85
Europe
FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S, FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S
OSPEDALE S. RAFFAELE DI MILANO
neoplastic and haematologic patologies patologie neoplastiche ed ematologiche
 
 
2008-000793-20: Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes

Ongoing
2
17
Europe
Rapmune (sirolimus), Rapmune (sirolimus)
Erasmus MC,
Paraneoplastic Neurological Syndromes associated with anti-Hu antibodies
 
 
2010-022655-29: Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial)

Ongoing
2
30
Europe
Rapamune, Rapamune
Erasmus MC
Epilepsy in children with Tuberous Sclerosis Complex
 
 
NCT01027000: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
2
68
US
rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Genentech, Inc., Biologics, Inc.
Leukemia, Lymphoma
01/16
04/23
2007-003275-40: New immunosuppressive treatments to reduce the rate of recurrence of hepatocellular carcinoma after liver transplantation

Ongoing
2
50
Europe
RAPAMUNE, RAPAMUNE
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Liver transplantation in patients with hepatocellular carcinoma
 
 
2005-000656-33: A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma

Ongoing
2
18
Europe
Rapamune, Cyclophosphamide, Rapamune, Cyclophosphamide 50 Tablets, Rapamune, Cyclophosphamide 50 Tablets
Royal Devon and Exeter NHS Foundation Trust
Plasma Cell Myeloma
 
 
NCT00792948: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting
2
97
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Sirolimus, AY 22989, AY-22989, AY22989, RAPA, Rapamune, Rapamycin, SILA 9268A, SILA-9268A, SILA9268A, WY 090217, WY-090217, WY090217, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
06/16
01/25
ChiCTR-ONRC-12002287: A Phase II Trial of Sirolimus for Complex Renal Angiomyolipoma

Recruiting
2
60
 
Oral sirolimus once daily ;No treatment
West China Hospital, Sichuan University; None, Self-financing
Renal angiomyolipoma
 
 
2015-005527-12: Sirolimus for the treatment of severe intestinal polyposis in patients with familial adenomatous polyposis (FAP); a pilot study Sirolimus voor de behandeling van ernstige intestinale polyposis bij patiënten met familiaire adenomateuze polyposis (FAP); een pilot studie

Ongoing
2
5
Europe
Tablet, Rapamune
Familial adenomatous polyposis Familiaire adenomateuze polyposis, Familial adenomatous polyposis Familiaire adenomateuze polyposis, Diseases [C] - Digestive System Diseases [C06]
 
 
MITO, NCT02505893: Minimal Islet Transplant at Diabetes Onset

Completed
2
6
Europe
Human pancreatic islet, ATG, Pegylated G-CSF, Rapamycin
Ospedale San Raffaele, Italian Diabetes Foundation
Diabetes Mellitus, Type 1
05/18
12/23
NCT00577278: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Checkmark P2 data - 1st line fNHL
Jun 2012 - Jun 2012: P2 data - 1st line fNHL
Completed
2
41
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, IDEC-In2B8, yttrium Y 90 ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, IDEC Y2B8, Y90 Zevalin, Y90-labeled ibritumomab tiuxetan, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia, Lymphoma
05/19
12/23
NCT03456700: Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Active, not recruiting
2
22
US
Auranofin, Ridaura, Laboratory Biomarker Analysis, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217
Mayo Clinic, National Cancer Institute (NCI)
Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
07/19
06/25
NCT01885689: Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Active, not recruiting
2
72
US
clofarabine, CAFdA, Clofarex, Clolar, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, allogeneic hematopoietic stem cell transplantation, tacrolimus, FK 506, Prograf, sirolimus, AY 22989, Rapamune, rapamycin, SLM, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome
12/19
12/24
ChiCTR-OIC-16008525: Efficacy and safety of rapamycin in the treatment of kaposiform hemangioendothelioma in infants

Recruiting
2
36
 
rapamycin
Guang Women and Children's Medical Center; Guang Women and Children's Medical Center, none
kaposiform hemangioendothelioma
 
 
NCT04461340: Efficacy and Safety of Sirolimus in COVID-19 Infection

Recruiting
2
40
RoW
Sirolimus, Rapamune
Alexandria University
COVID 19
10/20
11/20
2020-004359-34: NA NA

Not yet recruiting
2
10
Europe
Tablet
Assistance Publique – Hôpitaux de Paris (AP-HP), CRC
NA Sarcoïdose avec atteinte cutanée modérée à sévère du visage, NA Sarcoidose, Body processes [G] - Immune system processes [G12]
 
 
2020-000702-29: Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM). Ensayo Clínco para evaluar el efecto de Loratadina asociada a Rapamune en Linfagioleiomiomatosis (LAM).

Not yet recruiting
2
62
Europe
Loratadina Stada, Capsule, Loratadina STADA 10 mg
IDIBELL (Institut d’Investigació Biomédica de Bellvitge), Fondos de Investigación Sanitarioas (FIS)
EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS EFECTO DE LORATADINA EN LINFANGIOLEIOMIOMATOSIS, EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS EFECTO DE LORATADINA EN LINFANGIOLEIOMIOMATOSIS, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-001375-16: Study of the effectiveness of drugs selected depending on the molecular profile of diffuse intrinsic pontine glioma (DIPG) Badanie skuteczności leków dobranych w zależności od profilu molekularnego rozlanego glejaka pnia mózgu (diffuse intrinsic pontine glioma, DIPG)

Not yet recruiting
2
100
Europe
Film-coated tablet, Coated tablet, , Mekinist 0,5 mg film-coated tablets, Rapamune 1 mg coated tablets, Rapamune 1mg/ml oral solution
The Children's Memorial Health Institute, Medical Research Agency
diffuse intrinsic pontine glioma rozlany naciekający glejak mostu, brain stem tumor guz pnia mózgu, Diseases [C] - Cancer [C04]
 
 
SIRIUS, NCT04582136: Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Recruiting
2
146
RoW
Sirolimus, rapamycin, Placebo
Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation
Systemic Lupus Erythematosus
10/24
05/25
HLA-A29, NCT03871361 / 2018-003653-16: Abatacept in Patients With Birdshot HLA A29 Uveitis

Completed
2
15
Europe
Abatacept 125 MG/ML Prefilled Syringe, Orencia
Universitaire Ziekenhuizen KU Leuven, Ziekenhuis Netwerk Antwerpen (ZNA)
Eye Diseases, Uveitis
01/22
12/23
2021-000641-41: Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

Not yet recruiting
2
70
Europe
Powder and solvent for solution for injection, Tablet, Solu-Medrol, Rapamune
Helse Bergen HF, Haukeland University Hospital, HelseVest
Thyroid Eye Disease (TED) in patients with Graves' Diease., Thyroid Eye Disease (TED) in patients with Graves' Diease., Diseases [C] - Eye Diseases [C11]
 
 
NCT02642094: Aging Mammary Stem Cells and Breast Cancer Prevention

Terminated
2
58
US
Rapamycin, Sirolimus
LuZhe Sun, National Cancer Institute (NCI)
Cancer of Breast
03/22
05/22
ChiCTR2100043189: The safety and effectiveness of rapamycin (sirolimus) in the treatment of cerebral cavernous malformation

Recruiting
2
20
 
phase I: rapamycin capsule 1mg/m2 qd po; phase II: blank control ;phase I: blank control; phase II: rapamycin capsule 1mg/m2 qd po
The first hospital of Yichang; The First Hospital of Yichang, North China Pharmaceutical Company Ltd.
Cerebral cavernous malformation
 
 
THALA-RAP, NCT04247750: Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients

Recruiting
2
45
Europe
Sirolimus 0.5 mg
Università degli Studi di Ferrara, Rare Partners srl Impresa Sociale, Azienda Ospedaliero, Universitaria Meyer, Azienda Ospedaliero, Universitaria Pisana
Beta-Thalassemia
04/22
04/22
NCT05033964: The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Active, not recruiting
2
200
Europe, RoW
Percutaneous Coronary Intervention with drug eluting stents
Elixir Medical Corporation
Coronary Artery Disease
12/22
03/26
LORALAM, NCT05190627: Effect of Loratadine in Lymphangioleiomyomatosis

Recruiting
2
62
Europe
Loratadine, Clarytine, Placebo 10mg/day added to rapamycin for 12 months
Institut d'Investigació Biomèdica de Bellvitge
Lymphangioleiomyomatosis
12/22
12/23
HopES, NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Active, not recruiting
2
31
US
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), SM-88
Sarcoma Oncology Research Center, LLC, Tyme, Inc
Sarcoma, Ewing, Sarcoma
12/24
03/25
NCT04230499: Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Recruiting
2
30
US
Encapsulated Rapamycin (eRapa), eRapa; Encapsulated sirolimus
Rapamycin Holdings, Inc. dba Emtora Biosciences, Cancer Insight, LLC
Familial Adenomatous Polyposis
03/25
03/25
OASIS, NCT04720664: Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Terminated
2
11
US
SM-88
Georgetown University, Tyme, Inc
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
02/23
02/23
NCT02722668: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Active, not recruiting
2
16
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, MMF, Mycophenolate Mofetil, Sirolimus, Rapamycin, TBI, Total body irradiation, Umbilical cord blood cell infusion, UCB, ATG, Anti-thymocyte Globulin
Masonic Cancer Center, University of Minnesota
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
02/23
12/29
2023-000127-36: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP)

Not yet recruiting
2
15
Europe
Tablet, Rapamune
Karolinska Institutet, Åhlen-stiftelsen, Loo och Hans Ostermans stiftelse
Alzheimer's disease (AD) and mild cognitive impairment (MCI), Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT02583893: Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Completed
2
39
US
Sirolimus, Rapamycin, Mitoxantrone, Mitoxantrone hydrochloride, Novantrone, Etoposide, Etoposide phosphate, VP-16, Etopophos, Cytarabine, Cytosine arabinoside, Cytosar-U, Depocyt, ara-C
Sidney Kimmel Cancer Center at Thomas Jefferson University
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
04/23
05/23
STRIDE2, NCT02766465: Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed
2
138
US
Busulfan, Busulfex, Fludarabine, Fludara, r-ATG, Rabbit antithymocyte globulin, Hematopoietic Cell Transplant, Bone Marrow Transplant; BMT; HCT, Tacrolimus, Prograf®, Methotrexate, MTX, Standard of Care, Alemtuzumab, Lemtrada, Total Body Irradiation (TBI), Sirolimus, Rapamune, Melphalan, Alkeran, G-CSF, Granulocyte colony-stimulating factor
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, Dana-Farber Cancer Institute, National Marrow Donor Program, Emory University
Sickle Cell Disease
05/23
08/23
NCT04393454: Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Terminated
2
6
US
Sirolimus 2mg Tablet
Albert Einstein College of Medicine
Metastatic dMMR Solid Cancer, Solid Tumor, Cancer, Metastatic Solid Tumor
05/23
05/23
NCT04339101: Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Active, not recruiting
2
59
US
Fludarabine, Fluradosa, Itacitinib Adipate, INCB-039110 Adipate, INCB039110 Adipate, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sirolimus, AY 22989, RAPA, Rapamune, rapamycin, SILA 9268A, WY-090217, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
05/23
12/24
NCT03662412: Study of Sirolimus in Patients With Advanced Pancreatic Cancer

Recruiting
2
36
RoW
Sirolimus, Rapamycin
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pancreatic Cancer
06/23
06/23
Sickle-MAID, NCT03214354: Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Recruiting
2
12
Canada
Alemtuzumab, Campath, Total Body Irradiation, TBI, Sirolimus
University of Calgary
Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
07/28
07/28
2015-005416-15: Studie zu Sirolimus bei Patienten mit Überwuchssyndrom

Not yet recruiting
2
18
Europe
Rapamune® 1 mg/ml, Rapamune® 0,5 mg, Rapamune® 1 mg, Rapamune® 2 mg, Concentrate for oral solution, Tablet, Rapamune® 1 mg/ml Lösung zum Einnehmen, Rapamune® 0,5 mg überzogene Tabletten, Rapamune® 1 mg überzogene Tabletten, Rapamune® 2 mg überzogene Tabletten
Medical Center - University of Freiburg, University of Freiburg, Deutsche Forschungsgemeinschaft, Pfizer GmbH
Segmental overgrowth syndrome Überwuchssyndrom, Segmental overgrowth syndrome Überwuchssyndrom, Body processes [G] - Genetic Phenomena [G05]
 
 
NCT04775173: Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

Completed
2
79
RoW
Sirolimus, Rapamycin, Rapamune
West China Hospital
Kaposiform Hemangioendothelioma
08/23
08/23
NCT04176380: RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Recruiting
2
27
US
RAPA-201 Autologous T cells, RAPA-201 cells
Rapa Therapeutics LLC, Medical College of Wisconsin
Relapsed, Refractory Multiple Myeloma
10/23
10/23
NCT01869114: Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Active, not recruiting
2
57
US
Sirolimus, rapamycin, Rapamune, Azacitidine, 5-azacytidine, Vidaza
Sidney Kimmel Cancer Center at Thomas Jefferson University
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia
04/28
04/28
NCT03099356: Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Recruiting
2
19
US
Cyclophosphamide, Sirolimus
University of Michigan Rogel Cancer Center
Metastatic Thyroid Cancer
12/24
12/25
PEARL, NCT04488601: Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

Completed
2
129
US
Rapamycin, Sirolimus, Rapamune, Rapacan, Siromus, Raparen, Rapasim, Sirova, Placebo
AgelessRx, University of California, Los Angeles
Aging
12/23
12/23
REACH, NCT04629495: Rapamycin - Effects on Alzheimer's and Cognitive Health

Recruiting
2
40
US
Rapamycin, Sirolimus, RAPA, Placebo, Placebo capsule
The University of Texas Health Science Center at San Antonio
Mild Cognitive Impairment, Alzheimer Disease
03/26
03/26
NCT04742777: Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

Recruiting
2
12
US
rapamycin, Sirolimus
The University of Texas Health Science Center at San Antonio, The Claude D. Pepper Older Americans Independence Centers, National Institute on Aging (NIA)
Aging
12/25
06/26
NCT02105766: Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Recruiting
2
162
US
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy
National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
12/23
12/24
NCT03933904: Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Active, not recruiting
2
24
US
Sirolimus, Rapamune, Rapamycin
University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
06/24
06/25
AflacST1502, NCT02574728: Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Recruiting
2
60
US
Sirolimus, Rapamune, rapamycin, Celecoxib, Etoposide, Etopophos, Toposar, Cyclophosphamide, Cytoxan
Emory University, Cannonball Kids' Cancer Foundation, Hyundai Hope On Wheels
Cancer
02/25
02/25
NCT04861064: Weekly Sirolimus Therapy

Recruiting
2
24
US
Sirolimus
Medical University of South Carolina
Venous Malformation, Lymphatic Malformation
02/25
06/25
NCT05269849: Sirolimus for Nosebleeds in HHT

Active, not recruiting
2
10
Canada
Sirolimus
Unity Health Toronto, National Institutes of Health (NIH)
Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis
11/24
02/25
DREPHAPLO, NCT03240731: HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease

Active, not recruiting
2
18
Europe
bone marrow transplant
Centre Hospitalier Intercommunal Creteil, Keocyt, Association Clinique Thérapeutique Infantile du val de Marne
Sickle Cell Disease
03/24
09/25
SUN-RAY, NCT06358638: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

Recruiting
2
12
US
Daratumumab, Darzalex, Alemtuzumab, Campath-1H, Sirolimus, Rapamune, Total Body Irradiation, TBI
Children's National Research Institute, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Sickle Cell Disease
09/44
09/54
NCT03922724: Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Recruiting
2
330
US
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
National Cancer Institute (NCI)
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
06/25
06/29
SIRIUS, NCT05458492: Sirolimus in Cutaneous Sarcoidosis

Not yet recruiting
2
10
NA
Sirolimus
Assistance Publique - Hôpitaux de Paris
Sarcoidosis, Cutaneous Sarcoidosis
05/24
05/27
SIRGO, NCT04598815: Sirolimus for Graves' Orbitopathy (GO)

Not yet recruiting
2
54
Europe
Sirolimus, Rapamycin
University of Pisa
Graves Ophthalmopathy
05/24
05/25
Rapamycin, NCT05836025: Effect of in Ovarian Aging

Recruiting
2
50
US
Rapamycin, Placebo
Columbia University
Perimenopausal
04/25
12/25
NCT06261060: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Recruiting
2
6
US
Sirolimus
M.D. Anderson Cancer Center
Familial Platelet Disorder, Hematopoietic
06/26
06/28
NCT04415476: Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)

Withdrawn
2
30
NA
Assigned Interventions, Tacrolimus, Mycophenolate mofetil, Prednisone, Sirolimus, Prograft, Cellcept, Deltasone, Prednicot, Rayos, Sterapred, Rapamune
University of Maryland, Baltimore
Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity
06/24
06/28
NCT02790515: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Recruiting
2
52
US
Anti-thymocyte globulin (rabbit), Thymoglobulin®, rabbit ATG, Blinatumomab, Blincyto, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, G-CSF, Filgrastim, Neupogen®, Melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran, Mesna, Mesnex, Rituximab, Rituxan™, Tacrolimus, FK506, Prograf®, Protopic®, Thiotepa, Thioplex® by Immunex, TESPA, TSPA, HPC,A Infusion, Transplant, CliniMACS, Cell Selection System, Sirolimus, Rapamycin, Rapamune®
St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
07/25
07/26
NCT04362293: Reduced Intensity Transplantation for Severe Sickle Cell Disease

Suspended
2
40
US
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
St. Jude Children's Research Hospital
Sickle Cell Disease
08/26
08/27
NCT06437574: Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Recruiting
2
140
US
Vytorin
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Prostate Cancer
02/28
05/28
RESUS, NCT05663944: REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The Proof of Concept Study

Active, not recruiting
2
45
Europe
Sirolimus 0.5Mg Tab, Rapamycin, 1st MRI scan, 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy, Placebo 0.5mg capsule, Placebo, Baseline Blood Tests, Baseline Clinical Examination, Week 1 - 5 Titration Blood Tests, Month 2 Clinical Examination, Month 2 Blood Tests, Month 4 Clinical Examination, Month 4 Blood Tests, Month 6 Clinical Examination, Month 6 Blood Tests, 2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy
Nottingham University Hospitals NHS Trust
Advanced Chronic Liver Disease
07/24
07/24
RAPA-4-PAF, NCT06308445: Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis

Not yet recruiting
2
25
Europe
Rapamycin
University Hospital, Toulouse
Familial Adenomatous Polyposis
08/29
08/29
Saturn, NCT06563817: The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

Recruiting
2
53
RoW
Rapamycin, Sirolimus
Beijing Tiantan Hospital
Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage, Secondary Normal Pressure Hydrocephalus, Post Hemorrhagic Hydrocephalus
05/25
07/25
NCT02979873: Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Recruiting
2
118
US
Sirolimus
National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
06/30
06/30
MAV-RAPA, NCT02042326: Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Recruiting
2
50
Europe
Sirolimus, Rapamune
Centre Hospitalier Universitaire, Amiens
Arteriovenous Malformations
09/24
09/24
BMT CTN 1507, NCT03263559: Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Active, not recruiting
2
80
US
Haploidentical Bone Marrow Transplantation, Hydroxyurea, Hydrea, Droxia, Rabbit-ATG, Thymoglobulin, Thiotepa, Chemo, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Total Body Irradiation, TBI, Mesna, Mesnex
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program
Sickle Cell Disease
09/24
12/24
NCT04094675: Sirolimus for Cowden Syndrome With Colon Polyposis

Active, not recruiting
2
10
US
Sirolimus, Rapamycin, Rapamune
Ohio State University, PTEN Research, Pfizer
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome, Cowden Syndrome, Bannayan Syndrome, Bannayan Zonana Syndrome, Polyposis
02/25
02/25
NCT03304678: Discovery of Sirolimus Sensitive Biomarkers in Blood

Recruiting
2
26
US
Sirolimus 2mg
National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis
09/25
09/25
NCT06504420: The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study

Not yet recruiting
2
70
NA
Sirolimus, Placebo
Peking University People's Hospital
Primary Antiphospholipid Syndrome
12/26
12/27
NCT03292861: The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Enrolling by invitation
2
60
US
Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
Cedars-Sinai Medical Center, Genzyme, a Sanofi Company
Heart Transplantation
10/24
10/25
NCT01428973 / 2010-024297-19: Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

Active, not recruiting
2
200
Europe
Mycophenolate mofetil, CellCept, Sirolimus, Rapamune
University of Liege, AZ Sint-Jan AV, Ziekenhuis Netwerk Antwerpen (ZNA), Jules Bordet Institute, University Hospital, Gasthuisberg, AZ-VUB, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital, Antwerp, Cliniques Universitaires de Mont-Godinne, Hospital de Jolimont, University Hospital, Ghent, AZ Delta
Graft-Versus-Host Disease, Hematological Malignancies
12/24
12/24
SUN, NCT03587272: Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease

Recruiting
2
30
Canada, US
Alemtuzumab, low dose total body irradiation, Sirolimus
Robert Nickel, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, The Children's Hospital at Montefiore, Morgan Stanley Children's Hospital
Sickle Cell Disease
11/25
11/25
NCT05925023: Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Recruiting
2
22
RoW
Sirolimus
Peking Union Medical College Hospital
Warm Autoimmune Hemolytic Anemia
12/24
12/25
RETIRE, NCT06552169: REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Not yet recruiting
2
34
US, RoW
Arm 1: SOC (mTOR + CNI), sirolimus or everolimus + tacrolimus, Arm 2A: TRACT/MONO mTOR, TRK-001 + sirolimus or everolimus, Arm 2B: TRACT/MONO CNI, TRK-001 + tacrolimus
Tract Therapeutics, Inc., PhiBio Therapeutics Inc, Taiwan Bio Therapeutics Inc.
Kidney Transplantation
12/26
12/30
RAPAMALYMPH, NCT03243019: Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

Recruiting
2
28
Europe
rapamycin, MRI, Rapamycin dosage
University Hospital, Lille, Ministry of Health, France
Lymphatic Malformation, Pediatric
02/25
02/25
NCT05237687: The Role of Sirolimus in Preventing Functional Decline in Older Adults

Recruiting
2
10
US
Sirolimus
Irina Timofte
Aging
09/25
11/25
ChiCTR2100050641: Efficacy and Safety of Sirolimus for Premature Ovarian Failure: A Prospective Study

Recruiting
2
20
 
Sirolimus
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Enterprise cooperation with North China Pharmaceutical Group Corporation
Primary ovarian failure
 
 
NCT05324384: Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

Recruiting
2
30
RoW
Sirolimus, Rapamycin, Rapamune
West China Hospital
Hemangioendothelioma
04/25
11/25
TSC-STEPS, NCT05104983: Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Recruiting
2
64
US
Sirolimus, Placebo
Darcy Krueger
Tuberous Sclerosis Complex, Epilepsy
06/25
06/26
NCI-2019-03188, NCT03970096: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting
2
120
US
Total-Body Irradiation, Total Body Irradiation, Whole-Body Irradiation, TBI, Whole Body Irradiation, SCT_TBI, Total-Body Irradiation Prior to Stem Cell Transplant, Thiotepa, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Triethylene, Triethylenethiophosphoramide, SH-105, Fludarabine, Fluradosa, Tacrolimus, Prograf, Protopic, FK-506, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Allogeneic TN-depleted CD34-preserved PBSCs, Allogeneic TND- CD34+ PBSCs, Donor-derived TN Cell Depleted CD34-enriched PBSCs, Naive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Farmitrexat, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metotrexato, Cyclophosphamide, Ciclofosfamida, Ciclofosfamide, Cicloxal, Claphene, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cytophosphan, Asta B 518, WR-138719, Peripheral Blood Stem Cell, PBSC, Peripheral Blood Stem Cells, peripheral stem cell, Peripheral Stem Cells, Cyclosporine, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, Sandimmune, SangCya, Sirolimus, RAPA, Rapamune, rapamycin, SILA 9268A, WY-090217, Busulfan, Bussulfam, Busulfanum, Busulphan, Busulfex, CB 2041, Glyzophrol, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Bone Marrow Aspiration and Biopsy, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Biospecimen Collection
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
12/26
12/28
AflacST1903, NCT04469530: Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Recruiting
2
50
US
Sirolimus, Rapamune, rapamycin, Cyclophosphamide, Cytoxan, Etoposide, VP-16, VePesid, Toposar, Etopophos, Celecoxib, Celebrex
Emory University, PeachBowl LegACy Fund
Solid Tumor
09/25
09/25
NCT00092222: Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active, not recruiting
2
75
US
Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
National Cancer Institute (NCI)
Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
10/25
10/25
NCT03121001: Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Recruiting
2
50
US
ATG, Thymoglobulin®, fludarabine, cyclophosphamide, Total body irradiation, Stem cell infusion, Sirolimus, mycophenolate mofetil
University of Illinois at Chicago
Sickle Cell Disease
11/25
11/25
NCT01241864: Islet Transplantation in Type 1 Diabetic Kidney Allograft

Recruiting
2
10
US
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
University of Chicago
Diabetes Mellitus, Type 1
12/25
12/25
CALM, NCT06091332: Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Single Centre, Randomised, Placebo-controlled Trial

Not yet recruiting
2
60
RoW
Sirolimus, Rapamycin, Starch flake
Huashan Hospital
Cavernous Malformations, Brain Stem Hemorrhage
12/25
12/25
 

Download Options